Ikarian Capital’s Biogen BIIB Stock Holding History

Ikarian Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,800	Closed	-$498K	–	120
2022 Q4	$498K	Sell	1,800 -68,700	-97%	-$19.4M	0.12%	57
2022 Q3	$18.8M	Sell	70,500 -41,700	-37%	-$8.86M	3.75%	5
2022 Q2	$22.9M	Hold	112,200	–	–	4.17%	4
2022 Q1	$23.6M	Buy	+112,200	New	+$24.4M	3.11%	5
2021 Q4	–	Sell	-167,500	Closed	-$47.4M	–	199
2021 Q3	$47.4M	Sell	167,500 -102,500	-38%	-$33.6M	3.34%	4
2021 Q2	$93.5M	Sell	270,000 -124,900	-32%	-$37.8M	7.56%	1
2021 Q1	$110M	Sell	394,900 -75,500	-16%	-$20.4M	3.72%	4
2020 Q4	$115M	Buy	470,400 +370,400	+370%	+$95.6M	5.08%	4
2020 Q3	$28.4M	Buy	+100,000	New	+$27.9M	2.05%	9
2020 Q2	–	Sell	-143,400	Closed	-$45.4M	–	180
2020 Q1	$45.4M	Buy	+143,400	New	+$43.5M	3.41%	5

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Ikarian Capital's BIIB Position: Q3 2025 in Review

Ikarian Capital sold out of Biogen (BIIB) in Q3 2025, closing a stake of 21,516 shares — an estimated $2.7M sold.

Ikarian Capital first reported a position in BIIB in Q1 2020 and held it in 14 quarters. The position peaked at $43.6M in Q2 2021. 905 funds tracked by Wall St. Rank hold BIIB as of Q3 2025.

Ikarian Capital reported no remaining Biogen position as of Q3 2025 after selling out during the quarter.
Ikarian Capital sold 21,516 Biogen shares in Q3 2025, an estimated $2.7M.
Ikarian Capital first reported a position in Biogen in Q1 2020 and held it in 14 quarters.
Ikarian Capital's Biogen position peaked at $43.6M in Q2 2021.
905 funds tracked by Wall St. Rank held Biogen as of Q3 2025.

Based on Ikarian Capital's 13F filing for Q3 2025, filed 14 Nov 2025.